Disclosures: Kamalpreet Hara: Nothing to Disclose, Alberto Calleri: Nothing to Disclose, Tiffany Wu: Nothing to Disclose, Vijay Shah: Boehringer Ingelheim: Consultant, GSK: Consultant, GENFIT SA: Consultant, Intercept Pharmaceuticals, Inc.: Advisor, Korro Bio, Inc.: Consultant, Mallinckrodt Pharmaceuticals: Advisor, Novo Nordisk A/S: Consultant, Resolution Therapeutics, Ltd.: Advisor, Seal Rock Therapeutics, Ltd.: Consultant, Surrozen: Advisor, Patrick Kamath: Sequana: Advisor, NovoNordisk: Advisor, Douglas Simonetto: Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose 1590 A PROSPECTIVE STUDY EVALUATING THE PREVALENCE OF STEATOTIC LIVER DISEASE AND ADVANCED FIBROSIS AND CIRRHOSIS IN OVERWEIGHT AND OBESE INDIVIDUALS IN THE UNITED STATES Alexander Yang 1 Monica Tincopa 1 Federica Tavaglione 2 Veeral Ajmera 1 Lisa Richards 1 Maral Amangurbanova 1 Christian Butcher 1 Christie Hernandez 1 Egbert Madamba 1 Seema Singh 1 Ricki Bettencourt 1 Bernd Schnabl 1 Claude Sirlin 1 Rohit Loomba 1 , 1 University of California, San Diego, 2 University Campus Bio-Medico of Rome Background: In 2023, new steatotic liver disease (SLD) nomenclature was introduced to include metabolic dysfunction-associated liver disease (MASLD), alcohol-associated liver disease (ALD), and the entity metabolic dysfunction and alcohol-associated liver disease (MetALD) accounting for those with both metabolic risk factors and significant alcohol use
(This range varies a little bit, depending on who is defining normal)
It becomes more likely as diabetes lasts longer, glucose control remains poor, and other risk factorssuch as hypertension and kidney diseaseaccumulate
Please do not ask questions that use sensitive or confidential information
